immunodeficiency Most primary immunodeficiencies, and some other hematological-inherited disorders, can only be cured by hematopoietic stem cell transplantation (HSCT). Until recently, this approach was largely limited to patients with an human leukocyte antigen (HLA)-genoidentical sibling. However, because about 70% candidates lack a suitable sibling donor, the use of either unrelated donors (URD) or more disparate genetically haploidentical family member donors (HMD) has been necessary to increase the number of patients who might benefit from allogeneic HSCT [1] [2] [3] [4] URD transplants are usually associated with increased risk of graft failure and graft-versus-host disease (GVHD) and decreased overall survival, compared to HLA-genoidentical transplants. 5, 6 This is due, at least in part, to donor/ recipient HLA mismatches that are not apparent with conventional serological testing. Indeed, the use of molecular typing techniques for all HLA loci has demonstrated that serological matching is insufficient to ensure an allelic match. 7, 8 High-resolution DNA-based typing for both HLA class I and class II alleles has greatly improved accuracy of donor selection. Matching of HLA class II DR and DQ alleles clearly reduces the risk of acute GVHD and improves survival after transplantation with URD. [8] [9] [10] [11] [12] However, the additional benefit of matching class I A, B and C using high-resolution DNA typing has mostly been investigated in adult patients with malignant hematological disorders, in particular chronic myeloid leukemia, where a degree of class I mismatch may confer some benefit from a graft-versus-leukemia (GVL) effect. [12] [13] [14] [15] [16] To date, this issue has not been addressed in a comparative manner in children with nonmalignant hematological disorders, as most studies have dealt largely with children with leukemia. [17] [18] [19] [20] [21] In this study, we compared clinical outcomes in 94 children with inherited diseases who underwent HSCT at a single pediatric institution between January 1994 and December 1998. Among them, 31 received marrow from a genoidentical sibling, 23 from an HLA-phenoidentical URD, and 40 from an HLA-haploidentical family member. The incidence of graft failure, the incidence of GVHD and the overall survival rate were compared in the different groups according to the level of donor/recipient compatibility.
Patients and methods

Patients
A total of 94 children received HSCT between January 1994 and December 1998 in the Pediatric ImmunoHematology Unit at Necker Hospital. Patients were aged 1-171 months (mean 39.9 months). All patients presented with inherited disorders defined as primary immunodeficiency (n ¼ 64), metabolic disease (n ¼ 12) or nonmalignant hematological disease (n ¼ 18). Children were divided into three groups according to the donor origin. The main characteristics of the patients are given in Table 1 . Group A consisted of 31 patients who received HLA-genoidentical marrow from a sibling donor (MSD). Group B consisted of 23 patients who received marrow from an URD. In group C, 40 patients received haploidentical marrow (HMD) from a family member who was genotypically identical for one HLA haplotype, and variably matched for the nonshared haplotype. These patients had no genotypically or phenotypically HLA-matched donor, or were likely to have rapid progression of disease preventing a search for an URD. Thus, the delay between diagnosis and time of grafting was shorter, and the age at time of transplantation younger than in the two previous groups.
Conditioning regimen consisted of busulfan (20 mg/kg total dose for children aged o6 years, 16 mg/kg for children aged 46 years, or 8 mg/kg for patients with severe combined immunodeficiency (SCID), from day À9 to day À6) and cyclophosphamide (200 mg/kg total dose from day À5 to day À2) in all patients. Three patients in group A, one in group B and one in group C did not receive any conditioning regimen because of severe combined immunodeficiency.
In URD and HMD recipients, prevention of graft rejection consisted of the use of anti-LFA1 monoclonal antibody (25.3, mouse IgG1, Pasteur Me´rieux, Paris, France) and anti-CD2 monoclonal antibody (BE-2, mouse IgG2b, Diaclone, Besanc¸on, France) as previously described. 22 From March 1998, rabbit anti-thymocyte globulin (Thymoglobulin R , IMTIX-SangStat, Lyon, France) was used instead for the prevention of graft rejection (25 mg/kg total dose).
Cyclosporine was given for GVHD prophylaxis to the MSD recipients and to five patients in the URD group. All other HSCT (ie 18 URD and all HMD marrows) were Tcell depleted using monoclonal antibodies or (since 1996) positive selection of CD34-positive cells, in order to prevent GVHD. When hematopoietic stem cells were T-cell depleted, no other GVHD prophylaxis was given after transplantation.
Donor selection and HLA typing
HLA typing was the major selection criterion, and secondary preference was given to younger, male donors. From 1994 to December 1997, we used serological testing using complement-dependent microlymphocytotoxicity for the HLA-A and B loci, and high-resolution genotyping using sequence-specific oligonucleotide hybridization or sequence-specific primer amplification for HLA-DR and DQ loci. No DRB1 or DQB1 mismatch was allowed for donor selection. DPB1 typing was not considered for selection of donors. From 1998, high-resolution genotyping using sequence-specific primer amplification was available for class I alleles (HLA-A, -B and -C), and was used prospectively for donor selection. Transplants are thus Table 1 Characteristics of 94 children patients undergoing transplantation with bone marrow from genoidentical, unrelated or haploidentical donors HLA matching and BMT for inherited diseases S Caillat-Zucman et al referred to as matched when there was HLA-A, -B, -C, -DR and -DQ allelic identity. Family member donors were typed using HLA-A and -B serological method, and HLA-DRB1 low-resolution genotyping. HLA-C and -DQB1 genotyping was performed retrospectively.
Assessment of HSCT outcome
All patients who survived for more than 28 days were considered evaluable for engraftment. Engraftment was considered to have occurred on the first of three consecutive days in which the absolute neutrophil count exceeded 500 /mm 3 . The presence of donor cells was demonstrated by HLA typing, karyotype analysis and detection of informative variable number of tandem repeat (VNTR) polymorphisms.
Patients were considered evaluable for acute GVHD if they engrafted successfully and evaluable for chronic GVHD, if they also survived for at least 100 days after transplantation. GVHD was graded according to Glucksberg et al 23 and confirmed whenever possible by appropriate histological studies.
Statistical analysis
Primary outcome of engraftment and GVHD were analyzed using continuity corrected w 2 tests, or, where frequencies were small, two-tailed Fisher's exact tests. Survival was assessed on the date of the last patient contact and analyzed on March 1, 2003. Univariate analysis of survival was performed by constructing Kaplan-Meier curves for subsets of patients and comparing them using the two-tailed logrank test. Comparisons of age, delay between diagnosis and transplantation, and mean follow-up between subgroups was made using non parametric MannWhitney U tests.
Results
HLA typing
Using retrospective HLA-A and -B allelic typing, and including HLA-C genotyping, in the 23 donor/recipient pairs from group B who were originally regarded as class I phenotypically matched, only 13 (56.5%) remained strictly identical after class I high-resolution genotyping, whereas 10 presented at least one class I mismatch. Among the 10 mismatched pairs, six were mismatched for HLA-B, five for HLA-C and three for HLA-A (Table 2) . Of the six HLA-B mismatched pairs, four were HLA-B35 allelic disparities. Four pairs were found to have two or more class I mismatches (A þ B, A þ C, or B þ C). Three out of the five HLA-C mismatched pairs had further HLA-A and/or -B incompatibilities identified at the molecular level. In donor/ recipient pairs from group C, the number of mismatched antigens at the unshared haplotype was calculated referring to either donor incompatibility (host-versus-graft response) or to recipient incompatibility (graft-versus-host response). In the host-versus-graft sense, 15 pairs were five or 6/10 identical for A, B, C, DR and DQ loci, that is no or just one phenotypic or genotypic match on the unshared haplotype, 18 pairs were seven or 8/10 identical, and seven pairs were 9/10 identical. In the graft-versus-host sense, 20 pairs were five or 6/10 identical, 14 pairs were seven or 8/10, and six pairs were 9/10.
Engraftment
Four patients (one in group A and three in group C) died before day 28 after transplantation, leaving 90 patients who could be evaluated. Engraftment of donor cells was achieved in 83 (92.2%) patients, and did not significantly differ among the three patient groups (Table 3 ). In the genoidentical group A, all 30 patients engrafted (100%). In the URD group B, 19 of the 23 valuable patients (82.6%) engrafted. Within this group, the proportion of children who engrafted was significantly lower in the mismatched (6/10, 60%) than in the matched subgroup (13/13, 100%, P ¼ 0.0004). Graft failure occurred in three patients with an HLA-B mismatch alone, and one patient mismatched for HLA-A and -B. Using Fisher's exact test, the odds of graft failure was significantly higher with donors who were mismatched for HLA-B than for those who were not (odds ratio ¼ 63, confidence interval [2.5-156], P ¼ 0.002). Of the four patients who failed to engraft, two died from infection, and two are still alive but with the chronic symptoms of their underlying disease. In the haploidentical group C, engraftment rate was 34 of the 37 valuable patients (91.9%). Seven patients were 9/10 matched group (100% engraftment rate), 15 out of 16 Table 2 HLA class I mismatches detected by high-resolution genotyping in 10 unrelated donor/recipient pairs Donor Recipient in the seven or 8/10 group (93.7%), and 12 out of 14 in the five or 6/10 group (85.7%). Graft failure occurred in three patients (two with a 5/10 matched graft), who all died within 5 months after transplantation.
GVHD
Of 81 children evaluable for GVHD, 30 presented acute GVHD of grades II-IV (37%) and 13 of grades III-IV (16%) ( Table 3 ). The incidence of acute GVHD was not significantly influenced by donor origin, due to T cell depletion of HSCT in groups B and C. In the genoidentical group A, two of 28 recipients presented acute GVHD of grades III-IV (7.1%). At time of study, they were still alive and well. In group B, three out of 19 evaluable children (15.8%) presented acute GVHD of grades III-IV, and one of them died. Only one of these three children had a class I-mismatch with the donor, whereas the others two received a fully identical transplant. The incidences of grades III-IV acute GVHD for the class I-matched and mismatched groups were 15.3 and 16.6%, respectively. Because the use of T-cell replete bone marrow has been associated with a higher incidence of severe GVHD, we analyzed separately the five patients in group B who received a T-cell replete transplant (HLA-matched in four cases, and one HLA-B þ C mismatch). Of these five children, one (HLA-matched) presented grade III-IV GVHD and died. Of 34 children evaluable in the haploidentical group C, eight (23.5%) presented grades III-IV acute GVHD. Six of them died. One child was in the 9/10-matched group (16.6% acute GVHD incidence), two in the seven or 8/10 matched group (15.3%) and five in the five or 6/10 matched group (33.3%) (difference not significant).
The incidence of limited and extensive chronic GVHD was comparable in the three groups, with a low overall incidence. One patient in group A presented limited chronic GVHD. In group B, two patients developed chronic extensive GVHD but survived. In group C, one patient presented limited chronic GVHD.
Infectious complications
Infection (bacterial, fungal or viral) contributed to the majority of deaths in all patients (23 of 35 deaths, 65.7%). In group A, 3/31 patients (9.7%) developed fatal infectious complications. Two patients died early after HSCT due to viral infection, and one developed secondary infectious complications of bacterial origin.
In group B, six patients out of 23 (26%) developed fatal infections, with all but one occurring during the first 3 months after transplantation. Three of these patients had more than one class I mismatch. The presence of one or more mismatch was significantly associated with the risk to develop severe infection (P ¼ 0.04, odds ratio ¼ 4.1).
In group C, 14 out of 40 patients (35%) died from infectious complications, mostly due to viral infections developed in the first 3 months after transplantation. In all, 11 of these cases (78.6%) were five or 6/10 matched with their donor (host-versus-graft or graft-versus-host sense). Using Fisher's exact test, there was a significant association between the presence of such haplotype mismatch and the risk of fatal infection (P ¼ 0.019, odds ratio ¼ 6.9).
Overall survival
The rate of survival in all patients was 62.7% (59/94). The median follow-up time for the 59 patients alive at last contact was 63 months (range 41-90 months). Age at time of transplantation, interval from diagnosis to HSCT, donor/recipient CMV status, or use of T-cell replete transplant did not significantly influence the rate of mortality in univariate analysis. There was no impact of diagnosis on survival. Very significant differences were observed, however, when comparing the rate of survival according to the donor origin (Table 3 and Figure 1, panel a) . Survival rate was 80.6% in group A (25/31 survivors), 65.2% in group B (15/23 survivors) and 47.5% in group C (19/40 survivors) (logrank test: P ¼ 0.023). In addition, the level of HLA compatibility between donor and recipient significantly influenced the rate of survival. Among the 15 surviving patients in group B, survival rate was 69.2% in the HLA- matched group (9/13 survivors), 83.3% in the onemismatch group (5/6 survivors) and 25% in the group with two or more mismatches (1/4 survivor). Therefore, survival rate was not significantly different between recipients of zero-or one-mismatch transplant (mean 73.7%). By contrast, it was dramatically lower in patients who received unrelated marrow with more than one mismatch compared to those grafted with zero or only one class I mismatch (logrank test: P ¼ 0.04). In group C, survival rate also greatly varied according to the number of HLA disparities between donor and recipient. Among the 19 children still alive at time of study, five were in the 9/10 matched group (83.3% survival rate), nine were in the seven or 8/10 group (64.3% survival), but only five were in the five or 6/10 haploidentical group (25% survival) (P ¼ 0.004).
We then compared the three patient groups A, B and C according to the number of mismatches in each group (Figure 1 , panel B, logrank P ¼ 0.0007). Survival rate was not significantly different in patients who received marrow from a genoidentical sib, from an URD with zero-or one class I mismatch, and from a family member donor with at least 7/10 HLA matches (80.6, 73.7 and 70%, respectively). Conversely, survival rate was extremely low when using unrelated marrow with more than one mismatch or less than 7/10 identical family member marrow (25% for both).
Discussion
This retrospective single-center study addresses for the first time the results of allogeneic HSCT with genoidentical donors in comparison with URD or haploidentical-related donors, in a large series of children affected by inherited hematological diseases. The principal finding of our study is that patients who received transplant from URD with zero or one HLA class I allele mismatch, or from family member donors that share at least seven of 10 HLA antigens, have a similar survival to patients transplanted with an HLAidentical sibling. Among these patients, the estimated survival is 75.7% at 5 years. By contrast, the use of URD with more than one mismatch, or highly HLA-disparate family members, is strongly deleterious, with a probability of survival of less than 25% at 5 years. Importantly, survival rate was not influenced by the age at time of grafting in any patient group.
An important aspect of our analysis is the precision with which HLA typing was determined in both the donors and the recipients. Indeed, a number of studies have shown that molecular typing methods are superior to serology in detecting HLA disparities. 7, 12, [24] [25] [26] In our center, highresolution HLA class II genotyping has been used routinely for selection of all URD for more than 8 years, but HLA class I DNA-based typing has been introduced more recently. In the present study, all pairs of unrelated HSCT were HLA class I and class II typed using molecular techniques. None of them had DR or DQ mismatch, but DP was not considered. By improving the resolution of class I typing however, it appeared following retrospective DNA typing, that only 56.5% of our donor/recipient pairs remained fully matched at the allelic level, while others presented at least one HLA-A, -B and/or -C allelic mismatch. In addition, HLA-C, -DRB1 and -DQB1 genotyping was completed in all pairs of family related HSCT, allowing for a comparable five loci HLA typing in the different patient groups.
Several groups have reported that matching of DRB1 and DQB1 decreased the risk of acute GVHD and improved survival after HSCT from unrelated marrow donors who were A-B-DR serologically matched. [8] [9] [10] [11] [12] [13] More recently, it was shown that the degree of HLA class I matching affected the incidence and severity of GVHD, graft rejection and overall survival. 13, 14, 27 Incompatibilities involving a molecular difference as small as one amino acid have been shown to generate vigorous alloreactive cytotoxic T-lymphocyte responses 7 that may lead to severe complications. 28, 29 Our study is the first to correlate HLA class I allelic differences with HSCT outcome in a homogeneous group of young patients affected with inherited disorders. The outcome of HSCT using URD was studied in children with Fanconi disease, but the effect of high-resolution molecular HLA typing was not as- sessed. 30 Our study complements a large multicentric European study recently conducted on 919 children with immunodeficiencies, showing that survival was significantly better after an HLA-identical than after mismatched HSCT in SCID patients, while in non-SCID, grafts from URD were almost as beneficial as those from genoidentical relatives. 31 However, HLA typing was not performed using molecular techniques until recently, and allelic differences were not considered in this study. In children with acute lymphoid leukemia, the presence of class I disparity increased the risk of graft failure, but did not significantly affect overall outcome. [18] [19] [20] 32 However, relapse was the main cause of death in these patients. In our series of children, the overall incidence of graft failure was low. The presence of an HLA-B mismatch in unrelated pairs significantly increased the risk of graft failure. However, the assessment of potential qualitative differences between HLA-A, -B or -C loci must await a larger series of transplants because the numbers of donors with a single A, B or C mismatch were too small for meaningful comparisons.
The incidence of grade III-IV acute GVHD and chronic GVHD was low in our series, probably because of the young age of the patients, because HLA class II matching was required for all URD, and because all hematopoietic stem cell transplants in group C, and the vast majority in group B, were T cell depleted. We analyzed the acute GVHD incidence in group B with and without the five patients who received a T-cell replete graft. No difference appeared, therefore justifying their inclusion in the statistical analysis.
The presence of a single class I mismatch, either in unrelated or family donor grafts, had no demonstrable effect on overall survival. This has previously been observed in patients with chronic myeloid leukemia, leading to the hypothesis that class I mismatch may have a beneficial graft-versus-leukemia effect. This is clearly not the only explanation since the presence of one class I mismatch was also tolerated well in our patients with inherited disorders. Infectious complications were the major cause of death, and were mostly observed in recipients of highly HLA class I-disparate donors. Because acute GVHD and infections are inter-related causes of death in these patients, new strategies must be developed in order to highly deplete alloreactive T cells, while preserving specific antiviral T-cell responses. 33, 34 In summary, our data support a donor selection strategy whereby patients with inherited hematological disease who lack a closely matched family donor be offered a zero or one class I mismatch URD, or a family donor sharing at least seven of 10 HLA antigens. By contrast, a highly HLAdisparate family or more than one mismatch URD should be avoided whenever possible. Overall, our data are encouraging, particularly for non-Caucasian children who have a low probability of finding a fully matched URD. By making the criteria for compatibility less strict and accepting URD with one class I allele mismatch, or partially matched family donor, the chance of rapidly identifying donors for children with severe hematological inherited disorders will increase.
